Wyeth to Build $280M Manufacturing Facility in China

Pharmaceutical and health care products concern Wyeth has just announced that it is in the process of building a manufacturing facility at Suzhou Industrial Park in China’s Jiangsu Province.The approximately 1.3 million square-foot facility, which carries a development price-tag of $280 million, will be one of the largest nutritional manufacturing plants in the world.Wyeth is developing the property, which will focus primarily on the production of infant formula milk powder, to address an increasing demand for nutritional products in China. Construction of the plant just kicked off and is on target to reach completion in 2010.Wyeth is no stranger to developing its own properties for custom use at home and abroad. “We build for our own use, we don’t lease,” a Wyeth spokesperson told CPN today. In 2005, the company completed construction of Grange Castle in Dublin, a 1.2 million-square-foot biotech production campus. In 2003, after having acquired Rhone-Poulenc Rorer Pharmaceutical’s 1.1 million-square-foot campus in Collegeville, Pa., for the global headquarters of its Wyeth Pharmaceuticals division, Wyeth concluded a $220 million expansion program that increased the property’s size to 1.8 million square feet. With regard to other construction activities, Wyeth is adding square footage at other nutritional manufacturing sites in Asia. It is spending $81.5 million to add a three-story utility building, a microbiology building and a wet process facility at its milk formula manufacturing plant in the Philippines, and the company is also making capital upgrades to its infant product production facility in Singapore.Based in Madison, N.J., Wyeth is a leading research-driven pharmaceutical and health care products company. In addition to pharmaceuticals, Wyeth develops and manufactures vaccines and biotechnology products. Company stock opened today at $41.27.